Drug delivery and targeting

Nature

Volumn 392, Issue 6679 SUPPL., 1998, Pages 5-10

  Langer, Robert ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEGRADATION; DRUG DOSAGE; DRUG INTERACTIONS; ENCAPSULATION; LIPIDS; OSMOSIS; POLYMERIC MEMBRANES; TOXICITY;

DRUG DELIVERY SYSTEMS; SIDE EFFECTS;

CONTROLLED DRUG DELIVERY;

CARMUSTINE; CLONIDINE; DRUG; ESTRADIOL; FENTANYL; GLYCERYL TRINITRATE; LIPOSOME; NICOTINE; POLYMER; SCOPOLAMINE; TESTOSTERONE;

DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENCAPSULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; POLYMERS;

EID: 0032580354     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Classen, D. C., Pestotnik, S. L., Evans, S. R., Lloyd, J. F. & Burke, J. P. Adverse drug events in hospitalized patients. J. Am. Med. Assoc. 277, 301-306 (1997).
2. Cramer, M. P. & Saks, S. R. Value of controlled release dosage forms. PharmacoEconomics 5, 482-504 (1994).
3. McKenney, J. M. & Harrison, W. L. Drug related hospital admissions. Am. J. Hosp. Pharm. 33, 792-795 (1976).
4. Langer, R. New methods of drug delivery. Science 249, 1527-1533 (1990).
5. Langer, R. Polymeric delivery systems for controlled drug release. Chem. Eng. Commun. 6, 15-48 (1980).
6. Folkman, J. & Long, D. The use of silicone rubber as a carrier for prolonged drug therapy. Surg. Res. 4, 139-142 (1964).
7. Langer, R. & Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature 263, 797-800 (1976).
8. Ogawa, Y., Yamamoto, M., Okada, H., Yashiki, T. & Shimamoto, T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid and copoly(lactic/glycolic acid). Bull. Chem. Pharm. 36, 1095-1103 (1988).
9. Costantino, H., Langer, R. & Klibanov, A. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J. Pharm. Sci. 83, 1662-1666 (1994).
10. Johnson, O. L. et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med. 3, 795-799 (1996).
11. Peppas, N. A. & Langer, R. New challenges in biomaterials. Science 263, 1715-1720 (1994).
12. Tamada, J. A. & Langer, R. Erosion kinetics of hydrolytically degradable polymers. Proc. Natl. Acad. Sci. USA 90, 552-556 (1993).
13. Leong, K. W., Brott, B. C. & Langer, R. Bioerodible polyanhydrides as drug-carrier matrices: I. characterization, degradation and release characteristics. J. Biomed. Mater. Res. 19, 941-955 (1985).
14. Ng, S. Y., Vandamme, T., Taylor, M. S. & Heller, J. Synthesis and erosion studies of self-catalyzed polyfortho ester)s. Macromolecules 30, 770-772 (1997).
15. Kadiyala, S., Lo, H., Ponticiallo, M. S. & Leong, K. in Biomedical Applications of Synthetic Biodegradable Polymers (ed. Hollinger, J.) 33-57 (CRC Press, Boca Raton, 1995).
16. Allcock, H. R. Design and synthesis of new biomaterials via macromolecules substitution. Ann. N.Y. Acad. Sci. 831, 13-31 (1997).
17. James, K. & Kohn, J. in Controlled Drug Delivery: Challenges and Strategies (ed. Park, K) 389-403 (American Chemical Society, Washington DC, 1997).
18. Brem, H. et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345, 1008-1012 (1995).
19. Valtonen, S. et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41, 44-49 (1997).
20. Laurencin, C. T. et al. Bioerodible poly(anhydrides) for antibiotic drug delivery: in vivo osteomyelitis treatment in a rat model system. J. Orthopaed. Res. 11, 256-262 (1993).
21. Jeong, B., Bae, Y. H., Lee, D. S. & Kim, S. W. Biodegradable block copolymers as injectable drug-delivery systems. Nature 388, 860-862 (1997).
22. Dunn, R. et al. Sustained release of cisplatin in dogs from an injectable implant delivery system. J. Bioact. Compat. Polym. 11, 287-300 (1996).
23. Peppas, N. A. & Sahlin, J. J. Hydrogels as mucoadhesive and bioadhesive materials: a review. Biomaterials 17, 1553-1561 (1996).
24. Lenaerts, V. & Gurny, R. (eds) Bioadhesive Drug Delivery Systems (CRC Press, Boca Raton, 1990).
25. Kohn, J. et al. Single-step immunization using a controlled release, biodegradable polymer with sustained adjuvant activity. J. Immunol. Methods 95, 31-38 (1986).
26. Burnham, N. L. Polymers for delivering peptides and proteins. Am. J. Hosp. Pharm. 51, 210-218 (1994).
27. Duncan, R., Dimitrijevic, S. & Evagorou, E. G. The role of polymer conjugates in the diagnosis and treatment of cancer. STP Pharma Sci. 6, 237-263 (1996).
28. Putnam, D. & Kopecek, J. Polymer conjugates with anticancer activity. Adv. In Polym. Sci. 122, 59-123 (1995).
29. Murakami, Y., Tabata, Y. & Ikada, Y. Tumor accumulation of poly(ethylene glycol) with different molecular weights after intravenous injections. Drug Deliv. 4, 23-31 (1997).
30. Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 6, 181-202 (1991).
31. Dang, W., Colvin, O. M., Brem, H. & Saltzman, W. M. Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix. Cancer Res. 54, 1729-1735 (1994).
32. 5-(2-hydroxyethyl)-L-glutamine]. J. Contr. Rel. 38, 245-266 (1996).
33. Park, J. W., Hong, K., Kirpotin, D., Papahadjopoulos, D. & Benz, C. C. Immunoliposomes for cancer treatment. Adv. Pharmacol. 40, 399-435 (1997).
34. Gregoiraidis, G. Engineered liposomes for drug delivery: progress and problems. Trends Biotechnol. 13, 527-537 (1995).
35. Torchilin, V. P. Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents. Immunomethods 4, 244-258 (1994).
36. Kirpotin, D. et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36, 66-75 (1997).
37. Spragg, D. D. et al. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc. Natl Acad. Sci. USA 94, 8795-8800 (1997).
38. Poiani, G. J. et al. Polymeric carrier of proline analogue with antifibrotic effect in pulmonary vascular remodeling. Am. J. Respir. Crit Care Med. 155, 1384-1390 (1997).
39. Li, S. et al. DC-Chol lipid system in gene transfer. J. Contr. Rel. 39, 373-381 (1996).
40. McLean, J. W. et al. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am. Physiol. Soc. 273, H387-H404 (1997).
41. Gregoriadis, G., Saffie, R. & de Souza, J. B. Liposome-mediated DNA vaccination. FEBS Lett. 402, 107-110 (1997).
42. Gref, R. et al. Biodegradable long-circulating polymeric nanospheres. Science 263, 1600-1603 (1994).
43. Vandorpe, J. et al. Long circulating biodegradable poly(phosphazene) nanoparticles with poly(phosphazene)-poly(ethyleneoxide) copolymer. Biomaterials 18, 1147-1152 (1997).
44. Cremers, H. F. M. et al. Improved distribution and reduced toxicity of adriamycin bound to albumin-heparin microspheres. Int. J. Pharm. 120, 51-61 (1995).
45. Leong, K. W. et al. DNA-polycation nanospheres as non-viral gene delivery vehicles. J. Cont. Rel. 53, 183-193 (1998).
46. Boussif, O. et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo polyethylenimine. Proc. Natl Acad. Sci. USA 92, 7297-7301 (1995).
47. Tang, M. X. & Szoka, F. C. The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther. 4, 823-832 (1997).
48. Edelman, E., Brown, L. & Langer, R. In vitro and in vivo kinetics of regulated drug release from polymer matrices by oscillating magnetic fields. J. Biomed. Mater. Sci. 21, 339-353 (1987).
49. Lavon, I. & Kost, J. Mass transport enhancement by ultrasound in non-degradable polymeric controlled release systems. J. Contr. Rel. (in the press).
50. Kwon, I. C., Bae, Y. H. & Kim, S. W. Electrically erodible polymer gel for controlled release of drugs. Nature 354, 291-293 (1991).
51. Peppas, N. A. Hydrogels and drug delivery. Curr. Opin. Colloid. Interface Sci. 2, 531-537 (1997).
52. Goldraich, M. & Kost, J. Glucose-sensitive polymeric matrices for controlled drug delivery. Clin. Mater. 13, 135-142 (1993).
53. Chen, G. & Hoffman, A. S. Graft copolymers that exhibit temperature-induced phase transitions over a wide range of pH. Nature 373, 49-53 (1995).
54. Yoshida, R. et al. Comb-type grafted hydrogels with rapid deswelling response to temperature changes. Nature 374, 240-242 (1995).
55. Lowman, A. M. & Peppas, N. A. Analysis of the complexation/dccomplexation phenomena in graft copolymer networks. Macromolecules 30, 4959-4965 (1997).
56. Heller, J. in Controlled Drug Delivery: Challenges and Strategies (ed. Park, K.) 127-146 (American Chemical Society, Washington DC, 1997).
57. Niven, R. W. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Therap. Drug Carrier Syst. 12, 151-231 (1995).
58. Patton, J. S. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 19, 3-36 (1996).
59. Schuster, J., Rubsamen, R., Lloyd, P. & Lloyd, J. The AERx aerosol delivery system. Pharm. Res. 14, 354-357 (1997).
60. Service, R. F. Drug delivery takes a deep breath. Science 277, 1199-1120 (1997).
61. Edwards, D. A. et al. Large porous aerosols for pulmonary drug delivery. Science 276, 1868-1871 (1997).
62. Florence, A. T. & Jani, P. U. Novel oral drug formulations: their potential in modulating adverse effects. Drug Safety 10, 233-266 (1994).
63. Eldridge, J. H. et al. Controlled vaccine release in the gut-associated lymphoid tissues: I. orally administered biodegradable microspheres target the Peyer's patches. J. Contr. Rel. 11, 205-214 (1990).
64. Desai, M. P., Labhasetwar, V., Amidon, G. L. & Levy, R. J. Gastrointestinal uptake of biodegradable micropartides: effect of particle size. Pharm. Res. 13, 1838-1845 (1996).
65. Florence, A. T. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm. Res. 14, 259-266 (1997).
66. Tabata, Y., Inoue, Y. & Ikada, Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 14, 1677-1685 (1996).
67. Chen, H. & Langer, R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm. Res. 13, 1378-1383 (1996).
68. Mathiowitz, E. et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386, 410-414 (1997).
69. Leone-Bay, A. et al. 4-[4-(2-Hydroxybenzoyl)amino]phenyl-butyric acid as a novel oral delivery agent for recombinant human growth hormone. J. Med. Chem. 39, 2571-2578 (1996).
70. Mustern, S. J. et al. Partially unfolded proteins efficiently penetrate cell membranes: Implications for oral drug delivery. J. Contr. Rel. 53, 259-267 (1998).
71. Yeh, P. Y., Berenson, M. M., Samawitz, W. S., Kopeckova, P. & Kopechek, J. Site-specific drug delivery and penetration enhancement in the gastrointestinal tract. J. Contr. Rel. 36, 109-124 (1995).
72. Henningfield, J. E. Nicotine medications for smoking cessation. N. Engl. J. Med. 333, 1196-1203 (1995).
73. Merino, V., Kalia, Y. N. & Guy, R. H. Transdermal therapy and diagnosis by iontophoresis. Trends Biotechnol. 15, 288-290 (1997).
74. Prausnitz, M. R., Bose, V. G., Langer, R. & Weaver, J. C. Electroporation of mammalian skin: a new mechanism to enhance transdermal drug delivery. Proc. Natl Acad. Sci. USA 90, 10504-10508 (1993).
75. Prausnitz, M., Edelman, E. R., Gimm, J. A., Langer, R. & Wearer, J.C. Transdermal delivery of heparin by skin electroporation. Bio/Technology 13, 1205-1209 (1995).
76. Mitragotri, S., Blankschtein, D. & Langer, R. Ultrasound-mediated transdermal protein delivery. Science 269, 850-853(1995).
77. Aspden, T. J. et al. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human tubinates and volunteers. J. Pharm. Sci. 86, 509-513 (1997).
78. Artursson, P., Lindmark, T., Davis, S. S. & Ilium, L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11, 1358-1361 (1994).
79. Sherwood, J. K., Zeidin, L., Whaley, K. J., Cone, R. A. & Saltzman, M. Controlled release of antibodies for longterm topical passive immunoprotection of female mice against genital herpes. Nature Biotechnol. 14, 468-472 (1996).
80. Pardridge, W. M. Drug delivery to the brain. J. Cerebral Blood Flow Metab. 17, 713-731 (1997).
81. Bartus, R. T. et al. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp. Neurol. 142, 14-28 (1996).
82. Mitra, A. (ed.) Ophthalmic Drug Delivery Systems 223-262 (Marcel Dekker, New York, 1993).
83. Krewson, C. E. & Saltzman, W. M. Transport and elimination of recombinant human NGF during long-term delivery to the brain. Brain Res. 727, 169-181 (1996).
84. Musch, D. C. et al. Treatment of cytomegalovirus retinitis with a sustained-release gancyclovir implant. N. Engl. J. Med. 337, 83-90 (1997).
85. Rodgers, C. & Edelman, E. R. Controlled release of heparin reduces neointimal hyperplasia in stented rabbit arteries: ramifications for local therapy. J. Intervent. Cardiol. 5, 195-202 (1992).
86. Simons, M., Edelman, E. R., DeKeyser, J.-L., Langer, R. & Rosenberg, R. D. Antisense c-myb oligonucleotides inhibit arterial smooth muscle proliferation in vivo. Nature 359, 67-70 (1992).
87. Hill-West, J. L., Dunn, R. D. & Hubbell, J. A. Local release of fibrinolytic agents for adhesion prevention. J. Surg. Res. 59, 759-763 (1995).
88. Levy, R. J. et al. Inhibition of calcification of bioprosthetic heart valves by local controlled release diphosphonate. Science 228, 190-192 (1985).
89. Goodson, J. M. Life on a string: development of the tetracycline fiber delivery system. Techn. Health Care 4, 269-282 (1996).
90. Brocchini, S., James, K., Tangpasuthadol, V. & Kohn, J. A combinatorial approach for polymer design. J. Am. Chem. Soc. 119, 4553-1554 (1997).
91. Narasimhan, B. & Peppas, N. A. in Controlled Drug Delivery: Challenges and Strategics (ed. Park, K.) 529-557 (American Chemical Society, Washington DC 1997).